Pfizer expects to complete purchase of Seagen on Thursday

Pfizer expects to complete purchase of Seagen on Thursday

Pfizer CEO Albert Bourla said the purchase of Seagen would help the battle against cancer
Pfizer CEO Albert Bourla said the purchase of Seagen would help the battle against cancer. Photo: JUSTIN SULLIVAN / GETTY IMAGES NORTH AMERICA/Getty Images via AFP/File
Source: AFP

Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.

"Pfizer and Seagen have now received all required regulatory approvals," Pfizer said in a news release that reported a key US antitrust waiting period had expired. "Pfizer expects to close the acquisition of Seagen on December 14."

The big US drugmaker announced the transaction on March 13, pointing to Seagen's prominence in innovative cancer treatment.

The purchase of Seagen "is good for patients in the battle against cancer," said Pfizer Chief Executive Albert Bourla.

After a surge in revenues due to its Covid-19 therapeutic Paxlovid and vaccine Comirnaty, Pfizer encountered a much more challenging financial environment in 2023 with the ebbing of the pandemic.

In October, the company reported a quarterly loss due to a $5.6 billion inventory write-down in Paxlovid and Comirnaty.

Read also

Amid economic hardship, Nigerian prophet plans to feed over 1000 children

Seagen, headquartered in Washington state, came to major drugmakers' attention with its work on antibody-drug conjugates that are "designed to preferentially kill cancer cells."

The European Union cleared the transaction in October, saying the takeover did not raise competition concerns and would not negatively impact prices of treatments.

But in order to win approval from US regulators with the Federal Trade Commission, Pfizer said it would donate the royalties from sales of Bavencio in the United States to the American Association for Cancer Research.

Bavencio, which is also sold as Avelumab, is a prescription medicine used to treat different forms of cancer, including a skin cancer known as Merkel cell carcinoma.

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.

Online view pixel